Literature DB >> 23175377

The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89.

Eva Maria Borst1, Jennifer Kleine-Albers, Ildar Gabaev, Marina Babic, Karen Wagner, Anne Binz, Inga Degenhardt, Markus Kalesse, Stipan Jonjic, Rudolf Bauerfeind, Martin Messerle.   

Abstract

Cleavage of human cytomegalovirus (HCMV) genomes as well as their packaging into capsids is an enzymatic process mediated by viral proteins and therefore a promising target for antiviral therapy. The HCMV proteins pUL56 and pUL89 form the terminase and play a central role in cleavage-packaging, but several additional viral proteins, including pUL51, had been suggested to contribute to this process, although they remain largely uncharacterized. To study the function of pUL51 in infected cells, we constructed HCMV mutants encoding epitope-tagged versions of pUL51 and used a conditionally replicating virus (HCMV-UL51-ddFKBP), in which pUL51 levels could be regulated by a synthetic ligand. In cells infected with HCMV-UL51-ddFKBP, viral DNA replication was not affected when pUL51 was knocked down. However, no unit-length genomes and no DNA-filled C capsids were found, indicating that cleavage of concatemeric HCMV DNA and genome packaging into capsids did not occur in the absence of pUL51. pUL51 was expressed mainly with late kinetics and was targeted to nuclear replication compartments, where it colocalized with pUL56 and pUL89. Upon pUL51 knockdown, pUL56 and pUL89 were no longer detectable in replication compartments, suggesting that pUL51 is needed for their correct subnuclear localization. Moreover, pUL51 was found in a complex with the terminase subunits pUL56 and pUL89. Our data provide evidence that pUL51 is crucial for HCMV genome cleavage-packaging and may represent a third component of the viral terminase complex. Interference with the interactions between the terminase subunits by antiviral drugs could be a strategy to disrupt the HCMV replication cycle.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23175377      PMCID: PMC3554196          DOI: 10.1128/JVI.01955-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

Review 1.  Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.

Authors:  R A Fisher
Journal:  Transpl Infect Dis       Date:  2009-02-18       Impact factor: 2.228

Review 2.  The bacteriophage DNA packaging motor.

Authors:  Venigalla B Rao; Michael Feiss
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

3.  Role of the UL25 protein in herpes simplex virus DNA encapsidation.

Authors:  Shelley K Cockrell; Minerva E Sanchez; Angela Erazo; Fred L Homa
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

4.  Conditional and reversible disruption of essential herpesvirus proteins.

Authors:  Mandy Glass; Andreas Busche; Karen Wagner; Martin Messerle; Eva Maria Borst
Journal:  Nat Methods       Date:  2009-07-05       Impact factor: 28.547

5.  Mutational analysis of the herpes simplex virus type 1 DNA packaging protein UL33.

Authors:  Frauke Beilstein; Martin R Higgs; Nigel D Stow
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

6.  Strep/FLAG tandem affinity purification (SF-TAP) to study protein interactions.

Authors:  Christian Johannes Gloeckner; Karsten Boldt; Marius Ueffing
Journal:  Curr Protoc Protein Sci       Date:  2009-08

Review 7.  Drug targets in cytomegalovirus infection.

Authors:  Graciella Andrei; Erik De Clercq; Robert Snoeck
Journal:  Infect Disord Drug Targets       Date:  2009-04

8.  Herpesvirus capsid association with the nuclear pore complex and viral DNA release involve the nucleoporin CAN/Nup214 and the capsid protein pUL25.

Authors:  David Pasdeloup; Danielle Blondel; Anabela L Isidro; Frazer J Rixon
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

9.  In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.

Authors:  Peter Lischka; Guy Hewlett; Tobias Wunberg; Judith Baumeister; Daniela Paulsen; Thomas Goldner; Helga Ruebsamen-Schaeff; Holger Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  2010-01-04       Impact factor: 5.191

10.  Evolutionarily conserved herpesviral protein interaction networks.

Authors:  Even Fossum; Caroline C Friedel; Seesandra V Rajagopala; Björn Titz; Armin Baiker; Tina Schmidt; Theo Kraus; Thorsten Stellberger; Christiane Rutenberg; Silpa Suthram; Sourav Bandyopadhyay; Dietlind Rose; Albrecht von Brunn; Mareike Uhlmann; Christine Zeretzke; Yu-An Dong; Hélène Boulet; Manfred Koegl; Susanne M Bailer; Ulrich Koszinowski; Trey Ideker; Peter Uetz; Ralf Zimmer; Jürgen Haas
Journal:  PLoS Pathog       Date:  2009-09-04       Impact factor: 6.823

View more
  39 in total

1.  Intracellular Distribution of Capsid-Associated pUL77 of Human Cytomegalovirus and Interactions with Packaging Proteins and pUL93.

Authors:  Pánja Köppen-Rung; Alexandra Dittmer; Elke Bogner
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

Review 2.  Herpesvirus Capsid Assembly and DNA Packaging.

Authors:  Jason D Heming; James F Conway; Fred L Homa
Journal:  Adv Anat Embryol Cell Biol       Date:  2017       Impact factor: 1.231

3.  Sensitivity of the C-Terminal Nuclease Domain of Kaposi's Sarcoma-Associated Herpesvirus ORF29 to Two Classes of Active-Site Ligands.

Authors:  Jennifer T Miller; Haiyan Zhao; Takashi Masaoka; Brittany Varnado; Elena M Cornejo Castro; Vickie A Marshall; Kaivon Kouhestani; Anna Y Lynn; Keith E Aron; Anqi Xia; John A Beutler; Danielle R Hirsch; Liang Tang; Denise Whitby; Ryan P Murelli; Stuart F J Le Grice
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

4.  Human cytomegalovirus resistance to deoxyribosylindole nucleosides maps to a transversion mutation in the terminase subunit-encoding gene UL89.

Authors:  Brian G Gentry; Quang Phan; Ellie D Hall; Julie M Breitenbach; Katherine Z Borysko; Jeremy P Kamil; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

5.  Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage.

Authors:  Yan Wang; Lili Mao; Jayakanth Kankanala; Zhengqiang Wang; Robert J Geraghty
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

Review 6.  Cytomegalovirus Vaccines: Current Status and Future Prospects.

Authors:  K M Anderholm; C J Bierle; M R Schleiss
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

7.  Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data.

Authors:  Yasuo Mori; Fumiaki Jinnouchi; Katsuto Takenaka; Takatoshi Aoki; Takuro Kuriyama; Masanori Kadowaki; Jun Odawara; Toshiyuki Ueno; Kentaro Kohno; Takuya Harada; Goichi Yoshimoto; Ken Takase; Hideho Henzan; Koji Kato; Yoshikiyo Ito; Tomohiko Kamimura; Yuju Ohno; Ryosuke Ogawa; Tetsuya Eto; Koji Nagafuji; Koichi Akashi; Toshihiro Miyamoto
Journal:  Bone Marrow Transplant       Date:  2020-11-02       Impact factor: 5.483

8.  Epstein-Barr virus BALF3 has nuclease activity and mediates mature virion production during the lytic cycle.

Authors:  Shih-Hsin Chiu; Meng-Chuan Wu; Chung-Chun Wu; Yu-Ching Chen; Su-Fang Lin; John T-A Hsu; Chung-Shi Yang; Ching-Hwa Tsai; Kenzo Takada; Mei-Ru Chen; Jen-Yang Chen
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 9.  Mechanisms of DNA Packaging by Large Double-Stranded DNA Viruses.

Authors:  Venigalla B Rao; Michael Feiss
Journal:  Annu Rev Virol       Date:  2015-09-10       Impact factor: 10.431

10.  Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.

Authors:  Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.